On October 20, 2025, CollPlant Biotechnologies announced the results of a head‑to‑head comparative study of its Collink.3D™ bioink versus the industry standard Matrigel® conducted by the Levenberg Lab at the Technion – Israel Institute of Technology. The study, performed in a controlled laboratory setting, showed that Collink.3D™ exhibited superior mechanical strength, elasticity, and stability, creating a reproducible environment that supports organized and long‑lasting tissue formation.
The findings position Collink.3D™ as a next‑generation, animal‑free extracellular matrix that could replace Matrigel® in 3D cell culture, disease modeling, and drug discovery. The global market for basement membrane matrices, including Matrigel, was valued at approximately $96 million in 2024 and is projected to reach $201 million by 2031, growing at a CAGR of 11.2%. By outperforming Matrigel, Collink.3D™ could capture a significant share of this expanding market and enhance CollPlant’s competitive positioning in regenerative medicine and aesthetics.
CEO Yehiel Tal emphasized the significance of the results: “We are very pleased with the outcome of this study by the Technion. The results reinforce Collink.3D™ as a biologically supportive and durable bioink that promotes cell organization and tissue development while maintaining structural integrity over time. We believe Collink.3D™ represents a strong, animal‑free alternative for tissue engineering, regenerative medicine, and drug discovery applications.” The study’s success underscores CollPlant’s leadership in plant‑derived recombinant human collagen technology and supports future commercialization efforts in multiple therapeutic and research markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.